共 50 条
- [21] A first-in-human phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancersANNALS OF ONCOLOGY, 2020, 31 : S145 - S145Harding, J.Hofheinz, R.Elez, E.Kuboki, Y.Geng, J.Schmohl, M.Dowling, E.Feng, Y.Rasco, D.
- [22] First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumorsJournal of Hematology & Oncology, 9Tianhong LiPatricia LoRussoMichael L. MaitlandSai-Hong Ignatius OuErkut BahceciHoward A. BallJung Wook ParkGeoffrey YuenAnthony Tolcher
- [23] First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumorsJOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9Li, TianhongLoRusso, PatriciaMaitland, Michael L.Ou, Sai-Hong IgnatiusBahceci, ErkutBall, Howard A.Park, Jung WookYuen, GeoffreyTolcher, Anthony
- [24] A phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumoursANNALS OF ONCOLOGY, 2019, 30Sarantopoulos, J.Fotopoulos, G.Tsai, F. Y. -C.Beg, M. S.Adjei, A. A.Lou, Y.Seetharam, M.Villalona-Calero, M. A.Melear, J.Janat-Amsbury, M.Beever, H.Mouritsen, L.Wade, M.Bryan, B. V.Bearss, D. J.
- [25] An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumorsANNALS OF ONCOLOGY, 2023, 34 : S495 - S495Dudek, M. A.Zaslona, Z.Blaszczyk, R.Grzybowski, M. M.Rejczak, T.Cabaj, A.Dera, P.Lisiecki, K.Iwanowski, P.Charitos, T.Fung, S.
- [26] A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumorsANNALS OF ONCOLOGY, 2022, 33 : S20 - S20Yun, T.Shin, S. J.Kim, D-W.Yun, C. H.Heo, S.Hyun, B.Kim, Y. S.Kim, J. S.Moon, Y. W.
- [27] A PHASE 1, FIRST IN HUMAN, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF TST005 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A802 - A802Chen, LeiTolcher, AnthonyGabrail, NashatBarve, MinalWu, XiaohuaZhang, JianShi, MichaelQi, ChuanYu, StevenYao, JennyWang, JianmingCavanaugh, Christopher
- [28] Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Gutierrez, MartinHamid, OmidShum, ElaineWise, David R.Balar, Arjun VasantWeber, Jeffrey S.LoRusso, PatriciaShafi, SabaRimm, David L.Tolcher, Anthony W.Basudhar, DebashreeDujka, Melanie ElizabethHeller, Kevin N.
- [29] Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Moore, Kathleen N.Bendell, Johanna C.Olszanski, Anthony J.Desai, MadhuriJansen, MendelScheyer, Richard DavidSenaldi, GiorgioLoRusso, Patricia
- [30] A phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiencyCANCER RESEARCH, 2012, 72Blackman, Samuel C.Gainer, Shelby D.Suttle, Benjamin B.Skordos, Konstantine W.Greshock, Joel D.Motwani, MonicaRoadcap, Lori T.Hardwicke, Mary Ann A.Wooster, Richard F.